What’s Going On With FedEx Stock Today

FedEx Corporation (NYSE: FDX) reported a fourth-qu

FedEx Corporation (NYSE:FDX) reported a fourth-quarter FY23 revenue decline of 10.22% year-over-year to $21.9 billion, missing the consensus of $22.72 billion. Adjusted EPS was $4.94, which beat the estimates of $4.89.

The company returned $2.7 billion to stockholders through stock repurchases and dividends during FY23.

FDX ended FY23 with Revenue of $90.2 billion, EPS of $15.48, and Adjusted Diluted EPS of $14.96.

Q4 Adjusted operating margin contracted to 8.1% from 9.2% in 4Q22.

The company stated that the Q4 results were negatively affected by continued demand weakness and cost inflation, partially offset by cost-reduction actions and U.S. domestic package yield improvement.

Also read: FedEx Q4 Earnings Preview: What Analysts Expect And How The Company Serves As A Bellwether For Economy

FY24 Outlook: FDX sees Flat to low-single-digit-percent revenue growth year over year.

It expects EPS of $15.00 to $17.00 before the MTM retirement plans accounting adjustments and $16.50 to $18.50 after, versus a consensus of $18.35. It sees CAPEX spending of $5.7 billion for FY24.

Analysts’ Reaction: Raymond James analyst Patrick Tyler Brown maintained the Outperform rating and lowered the price target to $270 from $280.

Stephens & Co. analyst Jack Atkins reiterates the Overweight rating and maintains a $290 price target.

Morgan Stanley analyst Ravi Shanker reiterated the Equal-Weight and raised the price target to $186 from $180.

Additionally, FedEx announced that its Executive Vice President and Chief Financial Officer, Michael C. Lenz, will retire effective July 31, 2023. 

The company stated that an external search was underway for his successor.

Price Action: FDX shares are trading lower by 3.04% at $224.61 premarket on Wednesday.

Photo via Wikimedia Commons

Total
0
Shares
Related Posts
Read More

ADC Therapeutics Announced Initial Safety Run‐In Results From Lotis-5 Phase 3 Trial Demonstrate ORR Of 75% & 40% CR Rate With No New Safety Signals

ADC Therapeutics SA (NYSE: ADCT) today announced that ZYNLONTA® (loncastuximab tesirine-lpyl) and camidanlumab tesirine (Cami) abstracts have been accepted for presentation at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022), which will be held in Houston, Texas from September 28–October 1, 2022.

ADCT